

Policy: MP142

Section: Medical Benefit Policy

Subject: Anodyne Infrared Therapy

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Anodyne Infrared Therapy

II. Purpose/Objective:

To provide a policy of coverage regarding anodyne infrared therapy

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community;
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an

illness, condition, injury or disability.

- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION: Anodyne Infrared Therapy (aka: Monochromatic Infrared energy (MIRE) Therapy) involves the use of a device to deliver monochromatic, near-infrared photo energy through contact with the skin. The energy is emitted by an array of super-luminous gallium aluminum arsenide diodes located on a flexible pad. The application of photo-energy is proposed to release nitric oxide from hemoglobin and other proteins which acts as a signaling molecule to relax smooth muscle in arteries, veins and lymph vessels.

EXCLUSIONS: The Plan does **NOT** provide coverage for Anodyne Infrared Therapy because it is considered **experimental, investigational or unproven**. The Geisinger Technology Assessment Committee evaluated this technology and concluded that there is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this test on health outcomes when compared to established tests or technologies.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in **MP 15 - Experimental Investigational or Unproven Services or Treatment**.

NOTE: Infrared treatment is covered when medically necessary as a heat modality in a physical therapy regimen

CODING ASSOCIATED WITH: Anodyne Infrared Therapy

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

97039 Unlisted modality (specify type and time if constant attendance)

97139 Unlisted therapeutic procedure (specify)

97799 Unlisted physical medicine / rehabilitation service or procedure

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Geisinger Technology Assessment Committee Triage Group. Anodyne Infrared Therapy for Treatment of Chronic Non-healing Wounds, Diabetic Peripheral Neuropathy or Lymphedema. Nov. 18, 2004.

Tricenturion, DMERC A, L12873, Infrared heating Pad Systems.

Hayes Inc. MIRE Therapy (Monochromatic Infrared Energy) for Peripheral Neuropathy. April 6, 2018

Hayes Inc. MIRE Therapy (Monochromatic Infrared Energy) for Treatment of Wounds. April 6, 2018

Kochman AB. Monochromatic infrared photo energy and physical therapy for peripheral neuropathy: influence on sensation, balance and falls. J Geriatr Phys Ther. 2004;27(1):16-19.

Pendergast JJ, Miranda G, Sanchez M. Improvement of sensory impairment in patients with peripheral neuropathy. Endocr Pract. 2004 Jan-Feb; 10(1):24-30.

Leonard DR, Farooqi MH, Myers S. Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy. Diabetes Care, Jan 2004;27(1):168-172.

Carnegie D. The use of monochromatic infrared energy therapy in podiatry. *Podiatry Management* Nov-Dec 2002;129-134.

Noble JG, Lowe AS, Baxter GD. Monochromatic infrared irradiation (90 MM): Effect of a multisource array upon conduction in the human median nerve. *J Clin Laser Med Surg* 2001;19(6):291-295.

Kochman AB, Carnegie DH, Burke TJ. Symptomatic reversal of peripheral neuropathy in patients with diabetes. *J Am Podiatr Med Assoc.* 2002 Mar;92(3):125-130.

Powell MW, Carnegie DE, Burke TJ. Reversal of diabetic neuropathy and new wound incidence: the role of MIRE. *Adv Skin Wound Care.* 2004 Jul-Aug;17(6):295-300.

Horwitz LR, Burke TJ, Carnegie D. Augmentation of wound healing using monochromatic infrared energy. *Adv Wound Care.* 1999 Jan-Feb;12(1):35-40.

McCurdy B. Is anodyne therapy the answer for peripheral neuropathy? *Podiatry Today* 2003 Apr; 16(4):78.

Thomasson TL. Effects of skin-contact monochromatic infrared irradiation on tendonitis, capsulitis and myofascial pain. *J Neurol Orthop Med Surg* 1996;16:242-245

Anodyne Therapy <http://www.anodynetherapy.com/Professionals.htm>

ECRI, HTAIS Hotline. Monochromatic Infrared Irradiation for the Treatment of Peripheral Neuropathy. 12/27/04

DeLellis SL, Carnegie DH, Burke TJ. Improved sensitivity in patients with peripheral neuropathy: effects of monochromatic infrared photo energy. *J Am Podiatr Med Assoc.* 2005 Mar-Apr;95(2):143-7.

Clift JK, Kasser RJ, Newton TS, Bush AJ. The effect of monochromatic infrared energy on sensation in patients with diabetic peripheral neuropathy. *Diabetes care.* 2005 December; 28(12):2896-2900.

ECRI, HTAIS Target database. Monochromatic infrared irradiation for peripheral neuropathic pain. Jan. 2006.

Harkless LB, DeLellis S, Carnegie DH, Burke TJ. Improved foot sensitivity and pain reduction in patients with peripheral neuropathy after treatment with monochromatic infrared photo energy- MIRE. *J Diabetes Complications* 2006 Mar-Apr; 20(2):81-7.

Lavery LA, Murdoch DP, Williams J, Lavery DC. Does Anodyne light therapy improve peripheral neuropathy in diabetes? *Diabetes Care* 2008;31(2):316-321.

Franzen-Korzendorfer H, Blackinton M, Rone-Adams S, McCulloch J. The effect of monochromatic infrared energy on transcutaneous oxygen measurements and protective sensation: Results of a controlled, double-blind, randomized clinical study. *Ostomy Wound Manage.* 2008;54(6):16-31.

Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Infrared Therapy Devices (270.6)

Centers for Medicare & Medicaid Services. National Coverage Analysis (NCA) CAG-00291N

Hsieh RL, Lo MT, Lee WC et al. Therapeutic effects of short-term monochromatic infrared energy therapy on patients with knee osteoarthritis: a double-blind, randomized, placebo-controlled study. *J Orthop Sports Phys Ther* 2012; 42(11):947-56.

Robinson CC, Klahr PDS, Stein C et al. Effects of monochromatic infrared phototherapy in patients with diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. *Braz J Phys Ther* 2017; 21(4):233-243.

Sousa DFM, Gonçalves MLL, Politti F, et al. Photobiomodulation with simultaneous use of red and infrared light emitting diodes in the treatment of temporomandibular disorder: Study protocol for a randomized, controlled and double-blind clinical trial. *Medicine (Baltimore).* 2019;98(6):e14391

Silva RSDL, Pessoa DR, Mariano RD, et al. Systematic review of photobiomodulation therapy (PBMT) on the experimental calcaneal tendon injury in rats. *Photochem Photobiol.* 2020;96(5):981-997.

Salehpour F, Khademi M, Hamblin MR. Photobiomodulation therapy for dementia: A systematic review of pre-clinical and clinical studies. *J Alzheimers Dis.* 2021 Apr 28

This policy will be revised as necessary and reviewed no less than annually.

Devised: 12/10/04

Revised: 12/05 (updated references); 12/06, 01/10 (keywords)

Reviewed: 12/07, 12/08, 1/11, 1/12, 1/13, 1/14 1/15, 1/16, 1/17, 12/17, 12/18, 12/19, 12/20, 12/21, 12/22

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.